Menu
1 min read · estimated
APPROVED USE
What FDA approved
For adults with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma after at least two systemic lines.
LAMPGEN ANALYSIS
Why it matters
The accelerated approval added a subcutaneous CD20-directed bispecific for later-line large B-cell lymphoma.
What research teams should watch
Verify histology and treatment history, and arrange step-up dosing and post-dose observation.
PRIMARY RECORDS